Atlas Trials

Study Comparing Isolated Pelvic Perfusion With TNF-α 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer

Clinical trial NCT00949039 · COMPLETED

Trial details

NCT number
NCT00949039
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Gynaecologic or Digestive Pelvic Cancer
Start date
2009-02-01
Primary completion
2014-03-01
Enrollment
101

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.